Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine

Trial Profile

Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs CYD TDV (Primary) ; IC 51
  • Indications Dengue; Japanese encephalitis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 08 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top